Morgan Stanley Puma Biotechnology, Inc. Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Puma Biotechnology, Inc. stock. As of the latest transaction made, Morgan Stanley holds 322,462 shares of PBYI stock, worth $1.66 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

322,462

Previous 262,538 22.82%

Holding current value

$1.66 Million

Previous $777,000 42.34%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	BUY	$2.74 - $3.72 $164,191 - $222,917	59,924 Added 22.82%	322,462 $1.11 Million
Q1 2025 May 15, 2025	SELL	$2.76 - $3.88 $21,516 - $30,248	-7,796 Reduced 2.88%	262,538 $777,000
Q4 2024 Feb 14, 2025	SELL	$2.42 - $3.39 $26,891 - $37,669	-11,112 Reduced 3.95%	270,334 $824,000
Q3 2024 May 14, 2025	SELL	$2.25 - $4.03 $95,127 - $170,384	-42,279 Reduced 13.06%	281,446 $717,000
Q3 2024 Nov 14, 2024	SELL	$2.25 - $4.03 $95,127 - $170,384	-42,279 Reduced 13.06%	281,446 $717,000
Q2 2024 May 14, 2025	BUY	$2.92 - $5.83 $155,901 - $311,269	53,391 Added 19.75%	323,725 $1.06 Million
Q2 2024 Oct 17, 2024	SELL	$2.92 - $5.83 $858,120 - $1.71 Million	-293,877 Reduced 47.58%	323,725 $1.06 Million
Q2 2024 Aug 14, 2024	SELL	$2.92 - $5.83 $858,120 - $1.71 Million	-293,877 Reduced 47.58%	323,725 $1.06 Million
Q1 2024 Oct 17, 2024	BUY	$4.29 - $7.4 $1.26 Million - $2.17 Million	293,877 Added 90.78%	617,602 $3.27 Million
Q1 2024 Aug 16, 2024	BUY	$4.29 - $7.4 $1.04 Million - $1.79 Million	241,312 Added 64.13%	617,602 $3.27 Million
Q1 2024 May 15, 2024	BUY	$4.29 - $7.4 $1.04 Million - $1.79 Million	241,312 Added 64.13%	617,602 $3.27 Million
Q4 2023 Aug 16, 2024	BUY	$2.23 - $4.49 $117,219 - $236,016	52,565 Added 16.24%	376,290 $1.63 Million
Q4 2023 Feb 13, 2024	BUY	$2.23 - $4.49 $83,555 - $168,235	37,469 Added 11.06%	376,290 $1.63 Million
Q3 2023 Nov 15, 2023	BUY	$2.63 - $4.09 $40,023 - $62,241	15,218 Added 4.7%	338,821 $891,000
Q2 2023 Aug 14, 2023	SELL	$2.6 - $3.58 $42,359 - $58,325	-16,292 Reduced 4.79%	323,603 $1.14 Million
Q1 2023 May 15, 2023	SELL	$2.21 - $4.82 $348,764 - $760,653	-157,812 Reduced 31.71%	339,895 $1.05 Million
Q4 2022 Feb 14, 2023	BUY	$2.12 - $5.08 $225,112 - $539,419	106,185 Added 27.12%	497,707 $2.11 Million
Q3 2022 Nov 14, 2022	SELL	$2.27 - $3.84 $56,618 - $95,777	-24,942 Reduced 5.99%	391,522 $928,000
Q2 2022 Oct 27, 2022	BUY	$1.64 - $3.3 $349,228 - $702,715	212,944 Added 104.63%	416,464 $1.19 Million
Q2 2022 Aug 15, 2022	BUY	$1.64 - $3.3 $349,228 - $702,715	212,944 Added 104.63%	416,464 $1.19 Million
Q1 2022 Oct 27, 2022	SELL	$2.13 - $3.24 $453,570 - $689,938	-212,944 Reduced 51.13%	203,520 $586,000
Q1 2022 May 13, 2022	SELL	$2.13 - $3.24 $160,695 - $244,438	-75,444 Reduced 27.04%	203,520 $586,000
Q4 2021 Feb 14, 2022	BUY	$2.85 - $6.58 $141,670 - $327,085	49,709 Added 21.68%	278,964 $848,000
Q3 2021 Nov 15, 2021	BUY	$6.63 - $9.39 $1.52 Million - $2.15 Million	229,255 New	229,255 $1.61 Million

Others Institutions Holding PBYI

# of Institutions

126

Shares Held

33.3M

Call Options Held

68.2K

Put Options Held

View Full List

About PUMA BIOTECHNOLOGY, INC.

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $235M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

More about PBYI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account